The Trump administration has announced agreements with nine additional pharmaceutical manufacturers aimed at reducing prescription drug prices in the United States under its Most-Favored-Nation (MFN) pricing initiative.
The latest agreements bring the total number of pharmaceutical manufacturers participating in the administration's MFN arrangements to 26 companies, covering approximately 89% of the branded drug market, according to a White House fact sheet released on August 31.
Nine pharmaceutical companies join the initiative
The newly announced agreements involve: Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa, Kirin, Sun Pharma, Teva Pharmaceuticals and UCB
Under the agreements, the companies will provide MFN pricing for medicines in the United States, with the policy seeking to align U.S. drug prices with the lowest prices paid by other developed countries.
Medicines for cancer, Parkinson's disease and other conditions
The companies' medicines cover a wide range of therapeutic areas, including hemophilia, Parkinson's disease, macular degeneration, glaucoma, liver disease, dermatological conditions and several types of cancer.
The White House also stated that every state Medicaid program will gain access to MFN drug prices for products manufactured by the nine companies. The administration expects the arrangements to generate billions of dollars in savings.
19.6 billion USD commitment to U.S. pharmaceutical manufacturing
Beyond drug pricing, the nine companies have collectively committed to invest at least $19.6 billion in U.S. manufacturing in the near term.
Several companies have also agreed to provide active pharmaceutical ingredients (APIs) for the U.S. Strategic Active Pharmaceutical Ingredients Reserve (SAPIR).
According to the White House, contributions include :
UCB: 163 tons of levetiracetam
Sun Pharma: 71.4 tons of clindamycin and 6.75 tons of doxycycline
Teva Pharmaceuticals: 45 metric tons of metronidazole and 4.8 tons of amlodipine
Astellas: 25 kg of tacrolimus
The initiative is intended to strengthen domestic pharmaceutical supply chains and reduce dependence on foreign sources during emergencies.
White House projects 600 billion USD in savings
The administration said its MFN agreements could generate an estimated $600 billion in total savings over the next decade, citing estimates from the Council of Economic Advisers.
The White House also reported that patients have saved more than $700 million through TrumpRx since its February 2026 launch. It further stated that more than 500,000 seniors have collectively saved $216 million on GLP-1 medicines since a $50-per-month program began in July.
Sun Pharma and Teva among a growing list of participating companies
The latest announcement expands the list of pharmaceutical manufacturers participating in the administration's MFN initiative to 26. The companies now listed by the White House include Pfizer, AstraZeneca, Eli Lilly, Novo Nordisk, Amgen, Bristol Myers Squibb, Gilead Sciences, GSK, Merck, Novartis, Sanofi, Johnson & Johnson, AbbVie, Regeneron, and others, alongside the nine newly announced companies.
The White House said the agreements are part of President Trump's broader effort to bring U.S. prescription drug prices closer to those paid in other developed countries while encouraging pharmaceutical manufacturing and strengthening the country's medicine supply chain.
